NCT06767813View on ClinicalTrials.gov

Clinical Study of TQB2868 Injection Combined With Anlotinib Capsule and Chemotherapy in the First-line Treatment of Metastatic Pancreatic Neoplasms

PHASE2RecruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

March 19, 2024

Primary Completion Date

November 30, 2026

Study Completion Date

November 30, 2026

Conditions
Pancreatic Neoplasms
Interventions
DRUG

TQB2868 injection

TQB2868 injection is an anti-PD 1/growth factor (GF)-β Receptor Type II (TGF-βRII) bifunctional fusion protein.

DRUG

Gemcitabine injection

Gemcitabine injection

DRUG

Albumin paclitaxel injection

Albumin paclitaxel injection

DRUG

Anlotinib capsules

Anlotinib capsules

Trial Locations (7)

200032

RECRUITING

Fudan University Shanghai Cancer Center, Shanghai

210000

NOT_YET_RECRUITING

Jiangsu Provincial People's Hospital, Nanjing

NOT_YET_RECRUITING

Nanjing Drum Tower Hospital, Nanjing

215006

NOT_YET_RECRUITING

The First Affiliated Hospital of Soochow University, Suzhou

325000

NOT_YET_RECRUITING

The First Affiliated Hospital of Wenzhou Medical University, Wenzhou

450000

RECRUITING

Henan Cancer Hospital, Zhengzhou

450039

NOT_YET_RECRUITING

The Second Affiliated Hospital of Zhengzhou University, Zhengzhou

All Listed Sponsors
lead

Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.

INDUSTRY